Recent Updates
Recently added Catalysts

Bacillus Clausii

Phase 3

Gastroenteritis | Small molecule | Other |Sanofi|Last Updated: Jan 21, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedPLACEBO_CONTROLLED
Total Trials1
Total Enrollment264
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00457353ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in ChildrenPHASE3 COMPLETED 264Mar 1, 2007 -Jan 21, 20091 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Reduction in duration of diarrhea
Throughout the treatment period
Incidence of adverse events
Throughout the study period
Secondary Endpoints
Mean number of stools per day
Throughout the treatment period
Effect on consistency of stools
Throughtout the treatment period
Vomiting episodes per day
Throughout the treatment period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORAdministration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
2PLACEBO_COMPARATORAdministration of Oral rehydration therapy
Interventions
NameTypeDescription
Bacillus ClausiiDRUGFor 5 days
Oral rehydration therapyOTHERFor 5 days
Unlock Study Design Details
Eligibility Criteria
Age Range6 Months — 5 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Non hospitalised infants and children attending clinic/outpatients with acute diarrhea (\>3 liquid or watery stools occurring in a 24-hour period) of less than 48 hours duration Exclusion Criteria: * History of presence of blood, pus, or mucus in stools * Severe dehydration ...

Countries:India
Unlock Eligibility Criteria